Personalized therapeutics of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Ling-ling Zhu,1 Zhi-jun Feng,2 Quan Zhou3
1Geriatric VIP Ward, Division of Nursing, 2Department of Urology Surgery, 3Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
We read with great interest the multicenter, prospective, comparative cohort study by Zhang et al1 who suggested that patients with uncontrolled or untreated hypertension and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) should be warned about a decrease in blood pressure on initiation of alfuzosin 10 mg therapy alone or concomitantly with antihypertensive medication. Here we discuss and share our perspectives on this issue.
View original paper by Zhang and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]